A: Adjusted mean change in HbA1c from baseline to week 24 (■, linagliptin; □, placebo). There was a between-group difference of −0.61% (−6.7 mmol/mol) in favor of linagliptin (95% CI −0.88 to −0.34% [−9.6 to −3.7 mmol/mol]; P < 0.0001). Error bars represent SE. B: Adjusted geometric mean of percentage change in UACR by quartiles of HbA1c reduction in the linagliptin group: ■, <0.1% (<1.1 mmol/L) HbA1c reduction; □, 0.10−0.59% (1.1−6.5 mmol/L) HbA1c reduction; ▥, 0.60−0.99% (6.6−10.8 mmol/L) HbA1c reduction; ▤, ≥1.0% (≥10.9 mmol/L) HbA1c reduction; P ≥ 0.05 (ANOVA F test). Error bars represent 95% CIs. C: Adjusted mean change in SBP from baseline to last value during treatment (■, linagliptin; □, placebo). Error bars represent SE. D: Adjusted geometric mean of percentage change in UACR by categories of SBP change in the linagliptin group: ■, SBP increase >1.0 mmHg; □, −1.0 mmHg ≤ SBP change ≤ +1.0 mmHg; ▥, SBP decrease >1.0 mmHg; P ≥ 0.05 (ANOVA F test). Error bars represent 95% CIs.